# A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide

> **NCT04903509** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 95 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 1820237
- **DRUG:** Placebo
- **DRUG:** Saxenda®
- **DRUG:** Paracetamol-ratiopharm®

## Key facts

- **NCT ID:** NCT04903509
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-08
- **Primary completion:** 2022-08-26
- **Final completion:** 2022-08-26
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2022-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04903509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04903509, "A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04903509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*